BHVN Stock Recent News

Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.

The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency of the merits of its data on the experimental drug.

Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appear to be optimistic about its post-buyout future.

At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric appeared first on Investor's Business Daily.

NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.